NL-OMON30746尚未招募3 期
A phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn's Disease (CD) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy - IM101-084
Bristol-Myers Squibb0 个研究点目标入组 16 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1) Subject is willing to participate in the study and has signed the informed consent
- •2) Subject must have had CD for at least 3 months from the time of initial diagnosis. Active CD must be confirmed by radiologic, endoscopic or histologic evidence within the previous 12 months. If previous confirmation of diagnosis is not available or if previous diagnosis is not deemed conclusive at time of screening, CD diagnosis should be confirmed by endoscopy, radiology or histology.
- •3) Subjects must satisfy at least one of the following criteria:
- •a) Having had an inadequate response to at least 1 of the following treatments (subjects may be currently receiving 1 of these medications or have received them previously):
- •i) oral aminosalicylates (e.g., mesalamine, sulfasalazine, olsalazine, balsalizide) at or above the approved label dose for at least 8 weeks and/or
- •ii) oral prednisone >= 30 mg/day (or equivalent) or budesonide >= 9 mg/day for at least 4 weeks and/or
- •iii) immunosuppressants (azathioprine >= 2 mg/kg/day or 6-mercaptopurine >= 1.0 mg/kg/day [or documentation of a therapeutic concentration of 6 thioguanine nucleotide] or methotrexate >= 15 mg/week) for at least 12 weeks and/or
- •iv) an approved anti-TNF agent at an approved labeled dose for at least 8 weeks
- •b) Have been intolerant to one of the above mentioned treatments (e.g., unable to achieve doses or treatment durations because of dose limiting side effects [e.g., leukopenia]).
- •4) Moderate to severe CD as measured by a CDAI score >= 220 and <= 450
- •5) hsCRP > Upper Limit of Normal (ULN)
- •6)Men and women, ages >=18
排除标准
- •1) WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 10 weeks after the study
- •2) WOCBP using a prohibited contraceptive method (there are no prohibited methods for this study)
- •3) Women who are pregnant or breastfeeding
- •4) Women with a positive pregnancy test on enrollment or prior to study drug administration
- •5) Diagnosis of Ulcerative or Indeterminate Colitis
- •6) CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic or ileal involvement
- •7) Suspected or diagnosed intra-abdominal or perianal abscess at screening
- •8) Known strictures or stenosis leading to symptoms or obstruction
- •9) Current evidence of fulminant colitis, toxic megacolon or bowel perforation
- •10) Subjects who are scheduled or anticipate the need for surgery, aside from dermatologic procedures
- •11) Subjects who have a history of clinically significant drug or alcohol abuse
- •12) Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, pulmonary, cardiac, neurological, ophthalmologic or cerebral disease. Concomitant medical conditions that in the opinion of the Investigator might place the subject at unacceptable risk for participation in this study
- •13) Subjects with a history of cancer within the last 5 years (other than non-melanoma skin cell cancers cured by local resection). Existing non-melanoma skin cell cancers must be removed prior to enrollment. Subjects with carcinoma in situ, treated with definitive surgical intervention, are allowed
- •14) Subjects at risk for tuberculosis (TB).
- •15) Subjects with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection (such as chronic pyelonephritis, osteomyelitis and bronchiectasis)
- •16) Female subjects who have had a breast cancer screening that is suspicious for malignancy, and in whom the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory or other diagnostic evaluations
- •17) A history of severe or anaphylactic infusion reaction after receiving a biologic agent, suspected to be associated with an immune response
研究者
相似试验
进行中（未招募）
1 期
Effects of a medication being studied (rilematovir) in infants and children and subsequently neonates in the hospital with a respiratory infection due to RSVRespiratory Syncytial VirusMedDRA version: 21.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002023-11-HUJanssen-Cilag International NV737
进行中（未招募）
1 期
Efficacy and safety of adding LX4211 (an investigational oral compound) for patients with Type 1 Diabetes Mellitus (T1D) who have inadequate control of their blood glucose (sugar) levels on insulin alone.Type 1 Diabetes MellitusEUCTR2014-005153-39-LTexicon Pharmaceuticals, Inc.750
进行中（未招募）
1 期
Effects of a medication being studied (rilematovir) in infants and children and subsequently neonates in the hospital with a respiratory infection due to RSVEUCTR2020-002023-11-SEJanssen-Cilag International NV737
进行中（未招募）
1 期
A Study of the Effects of AMG 334 to Prevent Migraine HeadachesEUCTR2014-004464-38-NLAmgen Inc852
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)Immunoglobulin A Nephropathy (IgAN)EUCTR2020-003084-26-CZChinook Therapeutics U.S., Inc.320